DrugDisc

A novel strategy for treating immune-suppressive breast cancer: pharmacological prevention of CD73 deubiquitination (Zhu et al., J Clinical Investigation 2024); a collaboration between the Wan (Emory), Zhang (Northwestern) and Bahar (Laufer Center)

A novel strategy for treating immune-suppressive breast cancer: pharmacological prevention of CD73 deubiquitination (Zhu et al., J Clinical Investigation 2024); a collaboration between the Wan (Emory), Zhang (Northwestern) and Bahar (Laufer Center) labs

Allosteric modulation of parathyroid hormone receptor (PTHR) for regulating calcium signaling and endocrine homeostasis (Sutkeviciute et al Nature Chem Biol, 2022); NIH-funded collaboration between the Bahar (Laufer Center) and Vilardaga (U of Pitts

Allosteric modulation of parathyroid hormone receptor (PTHR) for regulating calcium signaling and endocrine homeostasis (Sutkeviciute et al Nature Chem Biol, 2022); NIH-funded collaboration between the Bahar (Laufer Center) and Vilardaga (U of Pittsburgh) labs

Recognition of SARS-CoV-2 spike superantigenic segment by T cell receptors (Cheng et al., PNAS 2020); a collaboration between the Bahar (Laufer Center) and Arditi (Cedars Sinai/UCLA) labs

Recognition of SARS-CoV-2 spike superantigenic segment by T cell receptors (Cheng et al., PNAS 2020); a collaboration between the Bahar (Laufer Center) and Arditi (Cedars Sinai/UCLA) labs

Targeting Cyt c peroxidase activity by imidazole substituted fatty acids for treating Barth syndrome (Kagan et al., Nature Metabolism, 2024)

Targeting Cyt c peroxidase activity by imidazole substituted fatty acids for treating Barth syndrome (Kagan et al., Nature Metabolism, 2024)

Development of new methodology for pharmacophore modeling: Pharmmaker (Lee et al. Protein Sci 2020), a method and software tool developed by the Bahar lab for accelerating computer-aided drug discovery

Development of new methodology for pharmacophore modeling: Pharmmaker (Lee et al. Protein Sci 2020), a method and software tool developed by the Bahar lab for accelerating computer-aided drug discovery

Allosteric activation of tumor suppressor protein phosphatase (PP2A); HFSP-funded collaboration between Bahar (Laufer Center), Itzhaki (Cambridge, UK), Gordon (Victoria U) and Yang (Taiwan Tsinghua U)

Allosteric activation of tumor suppressor protein phosphatase (PP2A); HFSP-funded collaboration between Bahar (Laufer Center), Itzhaki (Cambridge, UK), Gordon (Victoria U) and Yang (Taiwan Tsinghua U)

Targeting of allosteric sites as a strategy for complementing orthosteric site targeting and alleviating drug resistance

Targeting of allosteric sites as a strategy for complementing orthosteric site targeting and alleviating drug resistance

Design, synthesis and characterization of positive allosteric modulators (PAMs) of excitatory amino acid transporter 2 (EAAT2) (Fontana et al. J Med Chem, 2024); a collaboration between Salvino (Wistar Institute), Fontana (Drexel) and Bahar (Laufer C

Design, synthesis and characterization of positive allosteric modulators (PAMs) of excitatory amino acid transporter 2 (EAAT2) (Fontana et al. J Med Chem, 2024); a collaboration between Salvino (Wistar Institute), Fontana (Drexel) and Bahar (Laufer Center)